Bioglutide (NA-931): Side Effects

Safety Overview#

Bioglutide (NA-931) has been evaluated for safety in two completed clinical trials: a 28-day Phase 1 multiple ascending dose study (n=74) and a 13-week Phase 2 parallel-arm trial (n=125). The safety database is limited in size and duration compared to approved anti-obesity medications (semaglutide's clinical program enrolled over 25,000 participants with up to 3+ years of follow-up). The information below reflects the available data as of early 2026.

The most notable feature of Bioglutide's safety profile to date is the remarkably low incidence of gastrointestinal adverse events compared to existing GLP-1 receptor agonists.

Gastrointestinal Adverse Events#

Phase 1 GI Safety#

In the Phase 1 trial (28 days, n=74):

• All observed GI adverse events were rated as insignificant or mild
• 84% of GI adverse events were classified as insignificant
• Notably, mild nausea and vomiting were not reported among any NA-931-treated subjects
• No GI-related treatment discontinuations

Phase 2 GI Safety#

In the Phase 2 trial (13 weeks, n=125):

• 83% of GI adverse events were classified as insignificant
• Mild nausea and vomiting were reported in 7.3% of NA-931-treated subjects
• Diarrhea was reported in 6.3% of treated subjects
• No clinically meaningful differences in GI adverse events compared with placebo
• No serious GI adverse events reported

Comparison with Existing GLP-1 Agonists#

The GI tolerability advantage of Bioglutide is its most distinguishing safety feature compared to existing incretin-based therapies:

If confirmed in larger Phase 3 trials, this GI tolerability profile would represent a significant clinical advantage. GI side effects are the primary reason patients discontinue GLP-1 agonist therapy, and their severity is the main barrier to dose escalation.

Possible Reasons for Lower GI Side Effects#

Several hypotheses may explain the lower GI adverse event rates with Bioglutide:

1. Multi-receptor distribution: By distributing metabolic effects across four receptor pathways rather than relying primarily on GLP-1R activation, each individual receptor may require less activation to achieve the overall metabolic effect, potentially reducing the dose-dependent GI effects of GLP-1R stimulation
2. Small molecule pharmacology: As a small molecule with different receptor interaction kinetics than peptide agonists, Bioglutide may produce a different pattern of GLP-1R activation (potentially less sustained receptor stimulation)
3. IGF-1R and GCGR modulation: The additional receptor activities may counterbalance some of the GI effects of GLP-1R activation through mechanisms that are not yet fully characterized
4. Short trial duration: It is important to note that the 13-week Phase 2 trial is shorter than the pivotal trials for semaglutide and tirzepatide, and adverse event rates may increase with longer exposure

Muscle Mass Preservation#

A distinctive safety-relevant finding is the preservation of muscle mass during Bioglutide-induced weight loss:

• No muscle loss was observed in Phase 1 or Phase 2 trials
• This is attributed to IGF-1 receptor agonism, which promotes muscle protein synthesis
• With existing GLP-1 agonists, lean mass loss typically accounts for 25-40% of total weight lost, which is a significant clinical concern, particularly in elderly patients

While this finding is clinically relevant, it should be interpreted cautiously: detailed body composition data (from DEXA or similar imaging) have not been published, and the specific methodology used to assess muscle mass in the trials has not been disclosed.

Serious Adverse Events#

No serious adverse events were reported in either the Phase 1 or Phase 2 clinical trials. However, the combined safety database of approximately 199 subjects with treatment durations of up to 13 weeks is insufficient to detect rare serious events. Larger Phase 3 trials will be essential for characterizing rare adverse effects.

Theoretical Safety Considerations#

Given the four-receptor mechanism of action, several theoretical safety considerations warrant monitoring in future trials:

IGF-1 Receptor Agonism#

• Chronic IGF-1R activation has theoretical associations with cell proliferation and cancer risk, though this depends on the degree and duration of activation
• Epidemiologic data on endogenous IGF-1 levels and cancer risk are mixed and context-dependent
• Long-term safety monitoring for neoplastic events will be important in Phase 3 and post-marketing

Glucagon Receptor Agonism#

• GCGR activation stimulates hepatic glucose output, which could theoretically worsen glycemic control in diabetic patients
• In Bioglutide, this effect is intended to be counterbalanced by concurrent GLP-1R and GIPR agonism
• Liver enzyme monitoring may be warranted given glucagon's hepatic effects
• Similar considerations apply to retatrutide and survodutide, which also include GCGR activity

GLP-1 Receptor Agonism (Class Effects)#

Based on the established GLP-1 agonist class, theoretical risks include:

• Pancreatitis: Rare with existing GLP-1 agonists; not reported with Bioglutide to date
• Gallbladder events: Associated with rapid weight loss; not reported in short trials
• Thyroid C-cell tumors: Rodent class effect for GLP-1 agonists; relevance to a small molecule with different receptor pharmacology is unknown
• Heart rate effects: Modest increases (2-4 bpm) seen with GLP-1 agonists; not reported for Bioglutide

Contraindications#

No formal contraindications have been established for Bioglutide, as it is an investigational drug without approved labeling. Standard precautions for investigational metabolic agents include:

• Known hypersensitivity to the active substance or excipients
• Pregnancy and breastfeeding (no reproductive toxicology data available)
• Severe hepatic or renal impairment (no data in these populations)

Drug Interactions#

No drug interaction studies have been published for Bioglutide. Potential interactions to consider based on the mechanism of action include:

• Insulin and sulfonylureas: GLP-1R and GIPR agonism may enhance insulin secretion, potentially increasing hypoglycemia risk with concomitant insulin or sulfonylureas
• Oral medications: The effect of Bioglutide on gastric emptying has not been characterized; if it delays gastric emptying (as GLP-1 agonists typically do), absorption of co-administered oral medications could be affected
• CYP-mediated interactions: Unknown; the metabolic pathway of Bioglutide has not been disclosed

A notable advantage is that Bioglutide does not require fasting or timing restrictions relative to other oral medications, unlike Rybelsus which has strict administration requirements.

Limitations of Current Safety Data#

• Small sample size: Combined safety database of approximately 199 subjects is insufficient to detect events occurring at rates below 1-2%
• Short duration: Maximum 13 weeks of exposure does not characterize chronic use safety
• Homogeneous population: Trial populations may not represent the diversity of real-world obesity populations
• No formal drug interaction studies: Potential interactions are theoretical
• No formal organ toxicology: Hepatic, renal, and cardiac safety have not been formally assessed
• No reproductive toxicology: Effects on fertility, pregnancy, and lactation are unknown
• Publication bias: Safety data are from sponsor press releases and conference abstracts, not independent analysis

Related Reading#

• Bioglutide (NA-931) overview and research guide
• Bioglutide (NA-931) dosing protocols
• Bioglutide (NA-931) risks and legal status